Pre-made Rontalizumab benchmark antibody ( Whole mAb, anti-IFNA1 therapeutic antibody, Anti-IFL/IFN3/leIF DD Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Rontalizumab biosimilar, Whole mAb, Anti-IFNA1 Antibody: Anti-IFL/IFN3/leIF DD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Rontalizumab is a humanized monoclonal antibody being developed by Genentech. As of November 2009, it is being investigated in a clinical trial for the treatment of systemic lupus erythematosus.、

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-494-1mg	1mg	3090
GMP-Bios-ab-494-10mg	10mg	Inquiry
GMP-Bios-ab-494-100mg	100mg	Inquiry
GMP-Bios-ab-494-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Rontalizumab biosimilar, Whole mAb, Anti-IFNA1 Antibody: Anti-IFL/IFN3/leIF DD therapeutic antibody
INN Name	Rontalizumab
Target	IFNA1
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	4z5r:WV:BA:UT:SR:KJ:ML:QP:ZY
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2009
Year Recommended	2010
Companies	Chugai Pharmaceutical;Genentech
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Systemic lupus erythematosus
Development Tech	na